120 related articles for article (PubMed ID: 25711919)
1. C-terminal heat shock protein 90 modulators produce desirable oncogenic properties.
Wang Y; McAlpine SR
Org Biomol Chem; 2015 Apr; 13(16):4627-31. PubMed ID: 25711919
[TBL] [Abstract][Full Text] [Related]
2. N-terminal and C-terminal modulation of Hsp90 produce dissimilar phenotypes.
Wang Y; McAlpine SR
Chem Commun (Camb); 2015 Jan; 51(8):1410-3. PubMed ID: 25333923
[TBL] [Abstract][Full Text] [Related]
3. Reinventing Hsp90 Inhibitors: Blocking C-Terminal Binding Events to Hsp90 by Using Dimerized Inhibitors.
Koay YC; Wahyudi H; McAlpine SR
Chemistry; 2016 Dec; 22(51):18572-18582. PubMed ID: 27859703
[TBL] [Abstract][Full Text] [Related]
4. How Selective are Hsp90 Inhibitors for Cancer Cells over Normal Cells?
Wang Y; Koay YC; McAlpine SR
ChemMedChem; 2017 Mar; 12(5):353-357. PubMed ID: 28139075
[TBL] [Abstract][Full Text] [Related]
5. Macrocycles that inhibit the binding between heat shock protein 90 and TPR-containing proteins.
Ardi VC; Alexander LD; Johnson VA; McAlpine SR
ACS Chem Biol; 2011 Dec; 6(12):1357-66. PubMed ID: 21950602
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery.
Burlison JA; Blagg BS
Org Lett; 2006 Oct; 8(21):4855-8. PubMed ID: 17020320
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of heat shock protein 90 targeted compounds.
Cruz IN; Zhang Y; de la Fuente M; Schatzlein A; Yang M
Anal Biochem; 2013 Jul; 438(2):107-9. PubMed ID: 23563445
[TBL] [Abstract][Full Text] [Related]
8. A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.
Armstrong HK; Koay YC; Irani S; Das R; Nassar ZD; ; Selth LA; Centenera MM; McAlpine SR; Butler LM
Prostate; 2016 Dec; 76(16):1546-1559. PubMed ID: 27526951
[TBL] [Abstract][Full Text] [Related]
9. The first report of direct inhibitors that target the C-terminal MEEVD region on heat shock protein 90.
Buckton LK; Wahyudi H; McAlpine SR
Chem Commun (Camb); 2016 Jan; 52(3):501-4. PubMed ID: 26528929
[TBL] [Abstract][Full Text] [Related]
10. Combining an Hsp70 inhibitor with either an N- or C-terminal Hsp90 inhibitor produces mechanistically distinct phenotypes.
Wang Y; McAlpine SR
Org Biomol Chem; 2015 Mar; 13(12):3691-8. PubMed ID: 25679754
[TBL] [Abstract][Full Text] [Related]
11. Targeting the entry region of Hsp90's ATP binding pocket with a novel 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl amide.
Jeong JH; Oh YJ; Lho Y; Park SY; Liu KH; Ha E; Seo YH
Eur J Med Chem; 2016 Nov; 124():1069-1080. PubMed ID: 27783977
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of Hsp90 inhibitors: exploring the SAR of Sansalvamide A derivatives.
Sellers RP; Alexander LD; Johnson VA; Lin CC; Savage J; Corral R; Moss J; Slugocki TS; Singh EK; Davis MR; Ravula S; Spicer JE; Oelrich JL; Thornquist A; Pan CM; McAlpine SR
Bioorg Med Chem; 2010 Sep; 18(18):6822-56. PubMed ID: 20708938
[TBL] [Abstract][Full Text] [Related]
13. Structure based design of heat shock protein 90 inhibitors acting as anticancer agents.
Doddareddy MR; Thorat DA; Seo SH; Hong TJ; Cho YS; Hahn JS; Pae AN
Bioorg Med Chem; 2011 Mar; 19(5):1714-20. PubMed ID: 21306907
[TBL] [Abstract][Full Text] [Related]
14. Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.
Brandt GE; Blagg BS
Curr Top Med Chem; 2009; 9(15):1447-61. PubMed ID: 19860731
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Hsp90 C-terminal domain by the chemically accessible dihydropyrimidinone scaffold.
Strocchia M; Terracciano S; Chini MG; Vassallo A; Vaccaro MC; Dal Piaz F; Leone A; Riccio R; Bruno I; Bifulco G
Chem Commun (Camb); 2015 Mar; 51(18):3850-3. PubMed ID: 25656927
[TBL] [Abstract][Full Text] [Related]
16. C-terminal modulators of heat shock protein of 90 kDa (HSP90): State of development and modes of action.
Bickel D; Gohlke H
Bioorg Med Chem; 2019 Nov; 27(21):115080. PubMed ID: 31519378
[TBL] [Abstract][Full Text] [Related]
17. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
[TBL] [Abstract][Full Text] [Related]
18. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.
Kamal A; Thao L; Sensintaffar J; Zhang L; Boehm MF; Fritz LC; Burrows FJ
Nature; 2003 Sep; 425(6956):407-10. PubMed ID: 14508491
[TBL] [Abstract][Full Text] [Related]
19. Combined pharmacophore and structure-guided studies to identify diverse HSP90 inhibitors.
Sanam R; Tajne S; Gundla R; Vadivelan S; Machiraju PK; Dayam R; Narasu L; Jagarlapudi S; Neamati N
J Mol Graph Model; 2010 Feb; 28(6):472-7. PubMed ID: 20005756
[TBL] [Abstract][Full Text] [Related]
20. Co-crystalization and in vitro biological characterization of 5-aryl-4-(5-substituted-2-4-dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors.
Sharp SY; Roe SM; Kazlauskas E; Cikotienė I; Workman P; Matulis D; Prodromou C
PLoS One; 2012; 7(9):e44642. PubMed ID: 22984537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
